Literature DB >> 33261309

Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification.

Yanhua Bai1, Kennichi Kakudo2,3, Chan Kwon Jung4,5.   

Abstract

Advances in medical sciences and evidence-based medicine have led to momentous changes in classification and management of thyroid neoplasms. Much progress has been made toward avoiding overdiagnosis and overtreatment of thyroid cancers. The new 2017 World Health Organization (WHO) classification of thyroid neoplasms updated the diagnostic criteria and molecular and genetic characteristics reflecting the biology and behavior of the tumors, and newly introduced the category of borderline malignancy or uncertain malignant potential. Some neoplasms were subclassified, renamed, or redefined as a specific entity. This review introduces changes in the fourth edition WHO classification of thyroid tumors and updates the contemporary diagnosis and classification of thyroid tumors. We also discuss several challenges with the proposal of new diagnostic entities, since they have unique histopathologic and molecular features and clinical relevance.

Entities:  

Keywords:  Classification; Clinical decision-making; Diagnosis; Mutation; Prognosis; Thyroid neoplasms

Year:  2020        PMID: 33261309     DOI: 10.3803/EnM.2020.807

Source DB:  PubMed          Journal:  Endocrinol Metab (Seoul)        ISSN: 2093-596X


  8 in total

1.  Advantages of Small Incision Surgery in Thyroid Tumors.

Authors:  Wen Feng; Yuan Feng; Qixian Diao; Jian Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-11       Impact factor: 2.650

2.  Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin.

Authors:  Sheng-Yao Cheng; Alexander T H Wu; Gaber El-Saber Batiha; Ching-Liang Ho; Jih-Chin Lee; Halimat Yusuf Lukman; Mohammed Alorabi; Abdullah N AlRasheedi; Jia-Hong Chen
Journal:  Biology (Basel)       Date:  2022-02-17

3.  Thyroid Cancer Detection in a Routine Clinical Setting: Performance of ACR TI-RADS, FNAC, and Molecular Testing in Prospective Cohort Study.

Authors:  Tereza Grimmichova; Petra Pacesova; Martin Hill; Barbora Pekova; Marketa Vankova; Jitka Moravcova; Jana Vrbikova; Zdenek Novak; Karolina Mastnikova; Eliska Vaclavikova; Josef Vcelak; Bela Bendlova; Jana Drozenova; Vlasta Sykorova
Journal:  Biomedicines       Date:  2022-04-20

Review 4.  Papillary Thyroid Cancer Prognosis: An Evolving Field.

Authors:  Salvatore Ulisse; Enke Baldini; Augusto Lauro; Daniele Pironi; Domenico Tripodi; Eleonora Lori; Iulia Catalina Ferent; Maria Ida Amabile; Antonio Catania; Filippo Maria Di Matteo; Flavio Forte; Alberto Santoro; Piergaspare Palumbo; Vito D'Andrea; Salvatore Sorrenti
Journal:  Cancers (Basel)       Date:  2021-11-07       Impact factor: 6.639

5.  Clinical Significance of Circulating Tumor Cells (CTCs) and Survivin on Predicting Prognosis in Thyroid Cancer Patients.

Authors:  Xun Weng; Yujiao Cai
Journal:  Dis Markers       Date:  2022-01-31       Impact factor: 3.434

6.  Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer.

Authors:  Mohammad Hussein; Lauren Mueller; Peter P Issa; Muhib Haidari; Lily Trinh; Eman Toraih; Emad Kandil
Journal:  Biomedicines       Date:  2022-08-16

7.  Ultrasonographic characteristics of Hürthle cell neoplasms: prediction of malignancy.

Authors:  Min Je Kim; Jung Hee Shin; Soo Yeon Hahn; Young Lyun Oh; Sun Wook Kim; Tae Hyuk Kim; Yaeji Lim; Sanghyuk Lee
Journal:  Ultrasonography       Date:  2022-04-14

8.  Extracellular Vesicles as Signal Carriers in Malignant Thyroid Tumors?

Authors:  Małgorzata Grzanka; Anna Stachurska-Skrodzka; Anna Adamiok-Ostrowska; Ewa Gajda; Barbara Czarnocka
Journal:  Int J Mol Sci       Date:  2022-03-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.